潤邁德-B(02297.HK)擬全球發售2334.8萬股 預計7月8日掛牌上市
格隆匯6月27日丨潤邁德-B(02297.HK)發佈公吿，公司擬全球發售2334.8萬股股份，其中香港發售股份233.6萬股，國際發售股份2101.2萬股，另有15%超額配股權；2022年6月27日至6月30日招股，預期定價日為6月30日；發售價將為每股發售股份4.28-6.24港元，每手買賣單位1000股，入場費約6303港元；華泰國際為獨家保薦人；預期股份將於2022年7月8日於聯交所主板掛牌上市。
集團於2014年成立，是一家中國醫療器械公司，目前專注於基於冠狀動脈造影的血流儲備分數系統(“caFFR系統”)及基於冠狀動脈造影的微血管阻力指數系統(“caIMR系統”)的設計、開發及商業化。集團的核心產品(即caFFR系統及caIMR 系統)是創新的醫療器械，用於評估冠狀動脈狹窄和微血管功能障礙(冠狀動脈疾病(“CAD”)的相關起因)引起的心肌缺血的嚴重程度，其設計旨在替代壓力導絲的使用，大幅減少技術誤差和操作時間，從而改善生理評估。這兩個系統目前均單獨用於CAD的精準診斷。由於血流儲備分數(“FFR”)測量動脈的宏觀循環(佔所有動脈 5%)，而微循環阻力指數(“IMR”)則測量動脈的微觀循環(佔所有動脈95%)，因此聯合使用IMR和FFR可為CAD患者的冠狀動脈血液流通狀況提供全面評估。該兩個系統有望成為集團未來血管介入手術機器人的核心及關鍵模塊。
集團將可自全球發售收取所得款項淨額約5760萬港元，當中假設超額配股權並無獲行使及發售價為每股股份5.26港元(即本招股章程所述指示性發售價範圍的中位數)。假設發售價定為發售價範圍的中位數，集團目前擬將該等所得款項淨額47.1%撥作caFFR系統的持續研發、進一步臨牀研究、註冊備案的準備、生產及商業化的資金；32.9%將撥作caIMR系統的持續研發、進一步臨牀研究、註冊備案的準備、生產及商業化的資金；16.5%將撥作其他管線產品的持續研發、生產及商業化的資金；及3.5%將撥作一般營運資金及一般公司用途。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
